Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Active, not recruiting · NCT02673333 · Registry updated 2026-04-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma | Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-04-06 | NCT02673333 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| Merck Sharp & Dohme LLC | 650 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| University of Michigan (Data or Specimen Analysis Only) | Ann Arbor | United States | 1 |